These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8033761)

  • 1. Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts.
    Navaratnam V; Jamaludin A; Raman N; Mohamed M; Mansor SM
    Drug Alcohol Depend; 1994 Feb; 34(3):231-6. PubMed ID: 8033761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nontolerance to the opioid antagonism of naltrexone.
    Kleber HD; Kosten TR; Gaspari J; Topazian M
    Biol Psychiatry; 1985 Jan; 20(1):66-72. PubMed ID: 2981129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
    Schottenfeld RS; Chawarski MC; Mazlan M
    Lancet; 2008 Jun; 371(9631):2192-200. PubMed ID: 18586174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation.
    Legarda JJ; Gossop M
    Drug Alcohol Depend; 1994 Apr; 35(2):91-3. PubMed ID: 8055740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of naltrexone in preventing reabuse of heroin after detoxification.
    Shufman EN; Porat S; Witztum E; Gandacu D; Bar-Hamburger R; Ginath Y
    Biol Psychiatry; 1994 Jun; 35(12):935-45. PubMed ID: 8080893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of naltrexone in 155 heroin ex-addicts.
    Volavka J; Resnick RB; Kestenbaum RS; Freedman AM
    Biol Psychiatry; 1976 Dec; 11(6):679-85. PubMed ID: 999987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.
    Sullivan MA; Vosburg SK; Comer SD
    Psychopharmacology (Berl); 2006 Nov; 189(1):37-46. PubMed ID: 16972105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of heroin addicts using buprenorphine.
    Kosten TR; Morgan C; Kleber HD
    Am J Drug Alcohol Abuse; 1991 Jun; 17(2):119-28. PubMed ID: 1862786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR.
    Azatian A; Papiasvilli A; Joseph H
    J Addict Dis; 1994; 13(1):35-52. PubMed ID: 8018739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.
    San L; Pomarol G; Peri JM; Olle JM; Cami J
    Br J Addict; 1991 Aug; 86(8):983-90. PubMed ID: 1912753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.
    Comer SD; Collins ED; Kleber HD; Nuwayser ES; Kerrigan JH; Fischman MW
    Psychopharmacology (Berl); 2002 Feb; 159(4):351-60. PubMed ID: 11823887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with clonidine-naltrexone for rapid opiate detoxification.
    Senft RA
    J Subst Abuse Treat; 1991; 8(4):257-9. PubMed ID: 1787550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison.
    Judson BA; Carney TM; Goldstein A
    Drug Alcohol Depend; 1981 Jul; 7(4):325-46. PubMed ID: 7023894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopathology and mood during heroin use: acute vs chronic effects.
    Mirin SM; Meyer RE; McNamee HB
    Arch Gen Psychiatry; 1976 Dec; 33(12):1503-8. PubMed ID: 999452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
    Gonzalez JP; Brogden RN
    Drugs; 1988 Mar; 35(3):192-213. PubMed ID: 2836152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonidine and opiate receptor antagonists in the treatment of heroin addiction.
    Gerra G; Marcato A; Caccavari R; Fontanesi B; Delsignore R; Fertonani G; Avanzini P; Rustichelli P; Passeri M
    J Subst Abuse Treat; 1995; 12(1):35-41. PubMed ID: 7752296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of naltrexone in the treatment of young drug addicts].
    Waal H; Aamodt Ø; Olsen H
    Tidsskr Nor Laegeforen; 2003 Jun; 123(12):1662-4. PubMed ID: 12821983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.